The FDA has approved arsenic trioxide (Trisenox injection, Cell Therapeutics Inc, Seattle, Wash) for induction of remission or consolidation in patients with acute promyelotic leukemia (APL) who are refractory to or have relapsed from all transretinoic acid– and anthracycline-based chemotherapy....
A series of clinical investigations proved the effect of ATRA and arsenic trioxide combined treatment for different condition of patients with leukemia. ATRA combined with arsenic trioxide as first-line treatment can effectively improve the clinical outcomes of newly and relapsed APL [41,42,43,44,45...
leukemia involves the production of abnormal white blood cells -- the cells responsible for fighting infection. However, the abnormal cells in leukemia do not function in the same way as normal white blood cells. The leukemia cells continue to grow and divide...
109 patients were identified; 41 did not receive any treatment for the leukemia because of infectious and/or hemorrhagic complications of advanced disease. Median survival in this group was 4 days. The other 68 patients received one of two induction protocols: TAD from 1980 to 1985 (n = 23)...
New advances in the treatment of acute promyelocytic leukemia Objecive: Describe the treatment options of newly diagnosed and relapsed APL. Induction: The fusion PML/RAR gene provided the rationale for using all-trans... Dan,Douer - 《International Journal of Hematology》 被引量: 81发表: 2002年...
Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML). Biol ... E Klyuchnikov,N Kr?Ger,TH Brummendorf,... - 《Biology of Blood & Marrow Transplantation Journal of the American Society for Blood & ...
摘要: A 24-year old woman with a severe hemorrhagic diathesis was diagnosed with acute promyelocytic leukemia (APL). Treatment with all-trans retinoic acid (ATRA) and tranexaminic acid was started followed by idarubicin. The next day renal impairement was...
A chimeric toxin in which the cell surface binding domain of Pseudomonas exotoxin was replaced with mature human granulocyte colony-stimulating factor (G-CSF) was produced in Escherichia coli, partially purified and tested for its biological activity on a G-CSF-dependent murine myeloid leukemia cell...
Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was tr...
Kinase Inhibitors in Leukemia State of the Art Treatment of APL Investigational Agents in Myeloid Disorders Methodologic Issues in Investigation of Targete... D Scheinberg,J Jurcic 被引量: 0发表: 2004年 Novel human ribonuclease-based targeted therapeutics for the treatment of T cell acute lymphoblast...